University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 3P-18-2


Phase 1/2 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GP-2250 in Combination with Gemcitabine in Subjects with Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma Who Have Progressed on Prior Treatment with FOLFIRINOX Chemotherapy

Type: Treatment
Phase: Phase I/II
Status: Open to Accrual
Treatments: Chemotherapy: Systemic
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Diana Hanna, M.D.
Other Trial Staff:  Cristina De Leon, Coordinator, Chi Nguyen, Coordinator, Maria Sharma, Coordinator, Maria Sharma, Coordinator, Leila Andres, Coordinator, Fahim Raian, D.M., Edwin Smura, Coordinator, Charlean Ketchens, Coordinator, Jiayi Jiang, D.M., Raluca Agafitei, Coordinator, Xiomara Menendez, Coordinator, Noureddine Miloud, D.M., Yanli Wang, D.M., Rabia Rehman, Coordinator, Atessa Kiani, Coordinator, Diana Oganyesyan, Coordinator, Janelle Luevano, Coordinator, Ramy Farag, Coordinator, Alda Inveiss, Coordinator, Lauren Wagner, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.